Compare Stocks: AUPH, APGE, TGTX, and IBRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.03 +0.0%	$133.99	$35.39 ▼ $135.05	$8.40B	0.35	1.62 million shs	301,855 shs
AUPH Aurinia Pharmaceuticals	$16.06 -1.4%	$15.98	$10.34 ▼ $19.25	$2.14B	1.42	1.24 million shs	311,871 shs
IBRX ImmunityBio	$7.92 -1.6%	$7.88	$1.95 ▼ $12.43	$8.39B	0.03	22.00 million shs	2.45 million shs
TGTX TG Therapeutics	$53.40 -1.0%	$53.37	$26.76 ▼ $59.30	$8.17B	1.62	2.20 million shs	372,293 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+0.16%	+0.66%	+70.20%	+271.10%
AUPH Aurinia Pharmaceuticals	0.00%	-2.16%	+9.48%	+6.40%	+35.86%
IBRX ImmunityBio	0.00%	+3.34%	+12.27%	+11.19%	+244.02%
TGTX TG Therapeutics	0.00%	-0.63%	+3.65%	+44.16%	+83.87%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$135.03 +0.0%	$133.99	$35.39 ▼ $135.05	$8.40B	0.35	1.62 million shs	301,855 shs
AUPH Aurinia Pharmaceuticals	$16.06 -1.4%	$15.98	$10.34 ▼ $19.25	$2.14B	1.42	1.24 million shs	311,871 shs
IBRX ImmunityBio	$7.92 -1.6%	$7.88	$1.95 ▼ $12.43	$8.39B	0.03	22.00 million shs	2.45 million shs
TGTX TG Therapeutics	$53.40 -1.0%	$53.37	$26.76 ▼ $59.30	$8.17B	1.62	2.20 million shs	372,293 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+0.16%	+0.66%	+70.20%	+271.10%
AUPH Aurinia Pharmaceuticals	0.00%	-2.16%	+9.48%	+6.40%	+35.86%
IBRX ImmunityBio	0.00%	+3.34%	+12.27%	+11.19%	+244.02%
TGTX TG Therapeutics	0.00%	-0.63%	+3.65%	+44.16%	+83.87%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	2.16	Hold	$126.77	-6.12% Downside
AUPH Aurinia Pharmaceuticals	2.67	Moderate Buy	$17.67	10.00% Upside
IBRX ImmunityBio	2.71	Moderate Buy	$14.20	79.29% Upside
TGTX TG Therapeutics	2.44	Hold	$63.00	17.98% Upside

Current Analyst Ratings Breakdown

Latest AUPH, APGE, TGTX, and IBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/20/2026	AUPH Aurinia Pharmaceuticals	Bloom Burton Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/13/2026	APGE Apogee Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$81.00 ➝ $135.00
8/12/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
8/12/2026	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/7/2026	AUPH Aurinia Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$15.00 ➝ $16.00
8/7/2026	TGTX TG Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$65.00 ➝ $72.00
8/4/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$78.00
7/29/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
7/27/2026	TGTX TG Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $86.00
7/21/2026	AUPH Aurinia Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.23 per share	N/A
AUPH Aurinia Pharmaceuticals	$283.05M	7.55	$1.00 per share	16.08	$4.41 per share	3.64
IBRX ImmunityBio	$113.29M	74.09	N/A	N/A	($0.51) per share	-15.53
TGTX TG Therapeutics	$616.29M	13.26	$2.77 per share	19.25	$4.08 per share	13.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-29.88%	-28.08%	11/9/2026 (Estimated)
AUPH Aurinia Pharmaceuticals	$287.20M	$2.29	7.01	18.67	N/A	100.84%	26.11%	19.89%	11/3/2026 (Estimated)
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.74	19.49	20.15	2.31	55.22%	73.49%	34.14%	11/2/2026 (Estimated)

Latest AUPH, APGE, TGTX, and IBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	26.44	26.44
AUPH Aurinia Pharmaceuticals	0.07	5.42	4.97
IBRX ImmunityBio	N/A	5.72	5.70
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
AUPH Aurinia Pharmaceuticals	36.83%
IBRX ImmunityBio	8.58%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	24.30%
AUPH Aurinia Pharmaceuticals	10.40%
IBRX ImmunityBio	66.10%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
AUPH Aurinia Pharmaceuticals	300	133.05 million	119.21 million	Optionable
IBRX ImmunityBio	590	1.06 billion	359.28 million	Optionable
TGTX TG Therapeutics	290	153.07 million	139.49 million	Optionable

AUPH, APGE, TGTX, and IBRX Headlines

Recent News About These Companies

Legal & General Group Plc Invests $17.70 Million in TG Therapeutics, Inc. $TGTX

August 31 at 5:03 AM | marketbeat.com

Man Group plc Makes New Investment in TG Therapeutics, Inc. $TGTX

August 30 at 5:11 AM | marketbeat.com

Algert Global LLC Lowers Stock Position in TG Therapeutics, Inc. $TGTX

August 29 at 3:05 AM | marketbeat.com

Bank of New York Mellon Corp Takes $49.47 Million Position in TG Therapeutics, Inc. $TGTX

August 28 at 3:04 AM | marketbeat.com

PDT Partners LLC Acquires Shares of 41,585 TG Therapeutics, Inc. $TGTX

August 27, 2026 | marketbeat.com

TG Therapeutics Tests BRIUMVI in Schizophrenia: A New Angle for Long-Term Growth

August 26, 2026 | tipranks.com

TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)

August 26, 2026 | seekingalpha.com

Castleark Management LLC Buys Shares of 150,990 TG Therapeutics, Inc. $TGTX

August 26, 2026 | marketbeat.com

TGTX stock outperforms 95% of stocks. Here's why.

August 24, 2026 | msn.com

Great Lakes Advisors LLC Invests $1.11 Million in TG Therapeutics, Inc. $TGTX

August 23, 2026 | marketbeat.com

235,481 Shares in TG Therapeutics, Inc. $TGTX Bought by Deutsche Bank AG

August 23, 2026 | marketbeat.com

Stock Traders Purchase Large Volume of TG Therapeutics Call Options (NASDAQ:TGTX)

August 23, 2026 | americanbankingnews.com

TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors

August 22, 2026 | seekingalpha.com

BlackRock Inc. Takes Position in TG Therapeutics, Inc. $TGTX

August 22, 2026 | marketbeat.com

TGTX stock alert: What to know as takeover rumors swirl around TG Therapeutics

August 21, 2026 | msn.com

TG Therapeutics (NASDAQ:TGTX) Trading 10.1% Higher - Should You Buy?

August 21, 2026 | marketbeat.com

TG Therapeutics Target of Unusually Large Options Trading (NASDAQ:TGTX)

August 21, 2026 | marketbeat.com

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection

August 17, 2026 | marketbeat.com

Bank of America Corp DE Purchases 610,195 Shares of TG Therapeutics, Inc. $TGTX

August 13, 2026 | marketbeat.com

Assenagon Asset Management S.A. Lowers Stock Position in TG Therapeutics, Inc. $TGTX

August 13, 2026 | marketbeat.com

TG Therapeutics (TGTX) Q2 2026 Earnings Call Transcript

August 11, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH, APGE, TGTX, and IBRX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$135.03 +0.06 (+0.04%)

As of 01:33 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Aurinia Pharmaceuticals NASDAQ:AUPH

$16.06 -0.23 (-1.41%)

As of 01:33 PM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

ImmunityBio NASDAQ:IBRX

$7.92 -0.13 (-1.61%)

As of 01:33 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

TG Therapeutics NASDAQ:TGTX

$53.40 -0.53 (-0.98%)

As of 01:33 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUPH, APGE, TGTX, and IBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUPH, APGE, TGTX, and IBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUPH, APGE, TGTX, and IBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH, APGE, TGTX, and IBRX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Aurinia Pharmaceuticals NASDAQ:AUPH

ImmunityBio NASDAQ:IBRX

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AUPH, APGE, TGTX, and IBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AUPH, APGE, TGTX, and IBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AUPH, APGE, TGTX, and IBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH, APGE, TGTX, and IBRX Company Descriptions

Apogee Therapeutics NASDAQ:APGE

Aurinia Pharmaceuticals NASDAQ:AUPH

ImmunityBio NASDAQ:IBRX

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools